Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Stewart who wrote (208)	7/14/1999 6:50:00 PM
From: Thomas Stewart	Read Replies (1) \| Respond to of 668

Old (1997) WSJ article as a refresher. Swiped from Yahoo board. "Until recently, however, Wall Street hasn't been impressed with Creative BioMolecules, viewing it as a typical biotech company with a lot of promise but nothing to sell. Clinical trial for its product, OP-1, have dragged on for years because of difficulties in rounding up subjects. "...and in the first half of 1998, analysts expect the realease of final results of OP-1 trials, which focused on sever fractures that wouldn't heal." "We are anticipating that they will walk right through FDA approval, says Cathy Reese, an analyst with Avalon Research in Boca Raton, Fla., who has a strong buy rating on the stock. They have very stron data" "So is it too late to buy Creative BioMolecules after its recent run? No, analysts say. Assuming OP-1 gets FDA approval, they expect the stock will reach about $20 a share over the next year or so." "In a recent research report, she says that Stryker will be able to generate $485 million in sales from OP-1 in the year 2000. She predicts that Creative BioMolecules could reap $$96 million, or 85 cents a share, in profits that year from OP-1 and other lines of business."